Science & Technology
Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AI192061-01
Award Ceiling
$307K
Award Floor
$307K
Close Date
Apr 30, 2027
411 days leftTotal Funding
$307K
Expected Awards
1
Posted Date
May 9, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AI192061-01
Description
STTR Phase Phase I award: "Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications" awarded to MINK THERAPEUTICS INC in NEW YORK, New York. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $306,500. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.